CryoLife receives FDA 510 clearance for SynerGraft processed human pulmonary heart valves

Transplant News,  March, 2008  

• E-mail
• Print
• Link

CryoLife, Inc., Atlanta, GA, announced the US Food and Drug Administration (FDA) has given 510(k) clearance for its CryoValve[R] SG pulmonary human heart valve processed with the company's proprietary SynerGraft technology. The company says its SynerGraft technology is designed to remove allogeneic donor cells and cellular remnants from the valve without compromising the integrity of the underlying collagen matrix.

The CryoValve SG pulmonary human heart valve is indicated for the replacement of diseased, damaged, malformed or malfunctioning native pulmonary valves. The valve can be used in conjunction with right ventricular outflow tract reconstruction procedures, commonly performed in children with congenital heart defects. In addition, the valve can be used for pulmonary valve replacement during the Ross Procedure, an operation in which a patient's defective aortic valve is removed and replaced with his or her own pulmonary valve. The CryoValve is then surgically implanted in place of the removed native pulmonary valve.

At the FDA's request, CryoLife said it is planning a post-clearance study to seek evidence for the potential and implied long-term benefits of the SynerGraft process. Data to be collected is expected to include long-term safety and hemodynamic function, immune response, and explant analysis. The company says it believes that this information may help it ascertain whether the SynerGraft process reduces the immunogenicity of the transplanted heart valve and recellularizes with the recipients own cells.

CryoLife says it will be using the SynerGraft technology for the majority of its pulmonary valve processing and anticipates that the first CryoValve SG may be available for shipment late in the first quarter of 2008.

Contact: Web site: www.cryolife.com

COPYRIGHT 2008 Transplant Communications, Inc.
COPYRIGHT 2008 Gale, Cengage Learning